U.S.-China Heparin Scare Could Affect Indian Drug Makers
This article was originally published in PharmAsia News
Executive Summary
The scare surrounding tainted Chinese heparin could have an impact on Indian drug makers. The discovery that the active ingredient in blood-clotting drugs was tainted by Chinese suppliers has increased quality concerns by U.S. firms that obtain ingredients from China and India. Indian firms may be tempted to dismiss the concern as a problem China must deal with, but India often is mentioned as part of a general problem with sources of ingredients. One U.S. drug consultant says many companies are looking to Indian sources to replace Chinese sources, likely adding to U.S. scrutiny. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.